US2024043499A1PendingUtilityA1

Peptides for beta-cell survival and insulin production

70
Assignee: PROTEAN BIO INCPriority: Aug 7, 2022Filed: Aug 8, 2023Published: Feb 8, 2024
Est. expiryAug 7, 2042(~16 yrs left)· nominal 20-yr term from priority
Inventors:Kerry-Anne RyeMadhav Narasimha DevalarajaMaté BiroBlake CochranThomas H. KingSzun S. TayFeyza Colakoglu
C07K 14/775A61P 37/02
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject. 
     
     
         2 . The method of  claim 1 , wherein the peptide is configured to improve a score count of ACR20, ACR50 and ACR70 in the Rheumatoid arthritis. 
     
     
         3 . The method of  claim 1 , wherein the peptide is configured to improve SELENA SLEDAI scores in the lupus. 
     
     
         4 . The method of  claim 1 , wherein the peptide is configured to decrease formation of an auto antibody and reduces inflammation. 
     
     
         5 . The method of  claim 1 , wherein the peptide is configured to reduce numbness in limbs and increases mobility in limbs. 
     
     
         6 . The method of  claim 1 , wherein the peptide is configured to decrease thyroid secretion. 
     
     
         7 . The method of  claim 1 , wherein the peptide is configured to improve the AS40 scores in the Ankylosing spondylitis. 
     
     
         8 . The method of  claim 1 , wherein the peptide is configured to inhibit IL-2 or IL-7 or IL-15 driven expansion of primary human T cells. 
     
     
         9 . The method of  claim 1 , wherein the peptide is configured to inhibit primary CD8 T cell expansion. 
     
     
         10 . The method of  claim 1 , wherein the peptide is configured not to impair the T cell cytotoxicity. 
     
     
         11 . A method to treat a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Giant cell artereitis, Multiple Sclerosis, Grave's disease, Ankylosing spondylitis, and Guillian Bane Syndrome; and (2) monitoring the disease in the subject. 
     
     
         12 . The method of  claim 11 , wherein the peptide is configured to improve a score count of ACR20, ACR50 and ACR70 in the Rheumatoid arthritis. 
     
     
         13 . The method of  claim 11 , wherein the peptide is configured to improve SELENA SLEDAI scores in the lupus. 
     
     
         14 . The method of  claim 11 , wherein the peptide is configured to decrease formation of an auto antibody and reduces inflammation. 
     
     
         15 . The method of  claim 11 , wherein the peptide is configured to reduce numbness in limbs and increases mobility in limbs. 
     
     
         16 . The method of  claim 11 , wherein the peptide is configured to increase thyroid secretion. 
     
     
         17 . The method of  claim 11 , wherein the peptide is configured to improve the AS40 scores in the Ankylosing spondylitis. 
     
     
         18 . The method of  claim 11 , wherein the peptide is configured to inhibit IL-2 or IL-7 or IL-15 driven expansion of primary human T cells. 
     
     
         19 . The method of  claim 11 , wherein the peptide is configured to inhibit primary CD8 T cell expansion. 
     
     
         20 . The method of  claim 11 , wherein the peptide is configured not to impair the T cell cytotoxicity. 
     
     
         21 . The method of  claim 1 , wherein the peptide is configured to improve insulin sensitivity, C-peptide, glycemic index, and HbA1C in the Type 1 Diabetes.

Join the waitlist — get patent alerts

Track US2024043499A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.